Guangdong Association of Clinical Trials

Guangzhou, Guangdong

Oncologygene editingPhase III

What changed

Study registered, no phase assigned: Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection

4w agoTrial registeredJun 16, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

301 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE2 registered
Jan 30, 2026
Diffuse Large B-Cell Lymphoma (DLBCL) · RECRUITING · sponsor: Tianjin Medical University Cancer Institute and Hospital · CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
ClinicalTrials.gov · NCT07397832 (opens the source filing in a new tab)
Trial
PHASE1 registered
Nov 3, 2025
Peritoneal Metastases From Colorectal Cancer · RECRUITING · sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases
ClinicalTrials.gov · NCT07247396 (opens the source filing in a new tab)
Grant
R21 · $228k · non-dilutive
Sep 1, 2025
INDIANA UNIVERSITY INDIANAPOLIS · PI DONG, X. CHARLIE · NIAAA · award ends Aug 31, 2027 · Elucidation of the alcohol effect on tumor suppressor genes
NIH RePORTER · NIH RePORTER 11117928 (opens the source filing in a new tab)
Grant
R03 · $149k · non-dilutive
Jul 1, 2025
UNIVERSITY OF SOUTHERN MISSISSIPPI · PI XU, HAO · NIAID · award ends Jun 30, 2027 · Novel TNF Secretion Assays
NIH RePORTER · NIH RePORTER 11217588 (opens the source filing in a new tab)
Grant
R01 · $738k · non-dilutive
Jul 1, 2025
CASE WESTERN RESERVE UNIVERSITY · PI QI, XIN · NINDS · award ends Mar 31, 2030 · Regulation of ATAD3A in TDP43-associated ALS/FTD
NIH RePORTER · NIH RePORTER 11159127 (opens the source filing in a new tab)
Grant
R01 · $677k · non-dilutive
Jul 1, 2025
BRIGHAM AND WOMEN'S HOSPITAL · PI LUO, HONGBO R · NHLBI · award ends Mar 31, 2029 · Extending neutrophil survival in neutropenia-related pneumonia
NIH RePORTER · NIH RePORTER 11104380 (opens the source filing in a new tab)
Grant
R21 · $231k · non-dilutive
Jun 11, 2025
DUQUESNE UNIVERSITY · PI MENG, WILSON S · NIAID · award ends May 31, 2027 · Injectable 3D-Clustered Human Fibroblastic Reticular Cells for Expanding Regulatory T Cells
NIH RePORTER · NIH RePORTER 11138215 (opens the source filing in a new tab)
Grant
R01 · $844k · non-dilutive
Jun 6, 2025
ALBERT EINSTEIN COLLEGE OF MEDICINE · PI LAI, JONATHAN R. · NIAID · award ends May 31, 2030 · Human antibodies as broad alphavirus immunotherapeutics
NIH RePORTER · NIH RePORTER 11104757 (opens the source filing in a new tab)
Grant
R01 · $841k · non-dilutive
May 15, 2025
DUKE UNIVERSITY · PI XU, HANZHANG · NIA · award ends Feb 28, 2030 · Characterizing Family Structure, Care Utilization, and Well-Being among Persons with ADRD in the Asian Region
NIH RePORTER · NIH RePORTER 11131727 (opens the source filing in a new tab)
Grant
R01 · $718k · non-dilutive
May 6, 2025
UNIVERSITY OF GEORGIA · PI ZELTNER, NADJA · NICHD · award ends Apr 30, 2030 · Using 2D and 3D adrenal gland tissues to investigate developmental and disease paradigms
NIH RePORTER · NIH RePORTER 11138288 (opens the source filing in a new tab)
Grant
R35 · $687k · non-dilutive
May 1, 2025
COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ZHANG, HANRUI · NHLBI · award ends Apr 30, 2032 · Finding and pushing the limits of macrophage efferocytosis in atherosclerosis
NIH RePORTER · NIH RePORTER 11037155 (opens the source filing in a new tab)
Grant
R21 · $181k · non-dilutive
May 1, 2025
UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHEN, YU-CHIH · NCI · award ends Apr 30, 2027 · Halting Breast Cancer Metastasis by Blocking Cancer-MSC Engulfment
NIH RePORTER · NIH RePORTER 11125028 (opens the source filing in a new tab)
Grant
R01 · $578k · non-dilutive
Feb 24, 2025
UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LAI, JIANN-JYH · NIAID · award ends Jan 31, 2030 · Immunobiology of a novel human DAMP receptor, its murine homolog, & their ligand
NIH RePORTER · NIH RePORTER 11132308 (opens the source filing in a new tab)
Grant
R21 · $123k · non-dilutive
Feb 1, 2025
UNIVERSITY OF CHICAGO · PI YANG, XINAN HOLLY · NHLBI · award ends Nov 30, 2026 · Hedgehog Signaling as a regulator of progenitor differentiation for organ maintenance and disease
NIH RePORTER · NIH RePORTER 11045334 (opens the source filing in a new tab)
Grant
R21 · $222k · non-dilutive
Jan 22, 2025
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI YANG, XUEXIAN · NIAID · award ends Dec 31, 2026 · Control of the Survival Pathways in TH17 Cells
NIH RePORTER · NIH RePORTER 11035988 (opens the source filing in a new tab)
Grant
R61 · $345k · non-dilutive
Jan 22, 2025
UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YANG, XIANGDONG WILLIAM · NINDS · award ends Dec 31, 2026 · High-throughput small molecule screen to reduce endogenous level of Msh3 for disease-modifying HD therapy
NIH RePORTER · NIH RePORTER 11040927 (opens the source filing in a new tab)
Grant
F99 · $3k · non-dilutive
Jan 1, 2025
SLOAN-KETTERING INST CAN RESEARCH · PI CHEN, YAN-TING · NCI · award ends Aug 31, 2026 · Identifying and Targeting Drivers of Impaired Translation in Tumor-infiltrating CD8+ T-cells.
NIH RePORTER · NIH RePORTER 11250187 (opens the source filing in a new tab)
Grant
R01 · $256k · non-dilutive
Nov 25, 2024
UNIVERSITY OF CALIFORNIA-IRVINE · PI LIU, SIMIN · NIDDK · award ends Mar 31, 2026 · Asprosin, body weight, and risk of type 2 diabetes in U.S. men and women
NIH RePORTER · NIH RePORTER 11236632 (opens the source filing in a new tab)
Trial
NA registered
Nov 25, 2024
Gastric Cancer · RECRUITING · sponsor: The First Affiliated Hospital with Nanjing Medical University · Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy
ClinicalTrials.gov · NCT07056010 (opens the source filing in a new tab)
Trial
NA registered
Oct 28, 2024
Child Development, Activity, Motor · COMPLETED · sponsor: University of Alberta · Early Movers Pilot Intervention
ClinicalTrials.gov · NCT06538090 (opens the source filing in a new tab)
Grant
R01 · $404k · non-dilutive
Sep 1, 2024
CLEVELAND CLINIC LERNER COM-CWRU · PI ZHAO, JUN · NIDCR · award ends May 31, 2029 · CDK6-dependent metabolic reprogramming in KSHV pathogenesis
NIH RePORTER · NIH RePORTER 11179370 (opens the source filing in a new tab)
Grant
R01 · $313k · non-dilutive
Sep 1, 2024
UNIVERSITY OF TEXAS SAN ANTONIO · PI LIU, AIMIN · NIGMS · award ends May 31, 2026 · Protein-Derived Cofactor in Bifunctional Enzyme KatG from Mycobacterium tuberculosis
NIH RePORTER · NIH RePORTER 11168868 (opens the source filing in a new tab)
Grant
R01 · $340k · non-dilutive
Sep 1, 2024
UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WANG, BIN · NIGMS · award ends Jun 30, 2028 · Replication fork protection and innate immune response
NIH RePORTER · NIH RePORTER 11168806 (opens the source filing in a new tab)
Grant
R01 · $775k · non-dilutive
Aug 15, 2024
NEW YORK UNIVERSITY · PI QI, XIANG · NIA · award ends Apr 30, 2029 · Elucidating the Link Between Oral Health and Dementia Subtypes: A Multifaceted Study on the Biological Pathways and Social Determinants
NIH RePORTER · NIH RePORTER 11164603 (opens the source filing in a new tab)
Grant
R21 · $198k · non-dilutive
Aug 1, 2024
VANDERBILT UNIVERSITY · PI DONG, XIAOGUANG · NIBIB · award ends Apr 30, 2027 · Wirelessly Actuated Ciliary Stent for Minimally Invasive Treatment of Cilia Dysfunction
NIH RePORTER · NIH RePORTER 11140512 (opens the source filing in a new tab)
Grant
R01 · $541k · non-dilutive
Aug 1, 2024
EMORY UNIVERSITY · PI YANG, XIAOFENG · NIDCR · award ends Apr 30, 2029 · Intelligent and Personalized Online Adaptive Proton Therapy
NIH RePORTER · NIH RePORTER 11159734 (opens the source filing in a new tab)
Grant
U24 · $1.6M · non-dilutive
Jul 15, 2024
YALE UNIVERSITY · PI XU, HUA · NIMH · award ends Apr 30, 2029 · Coordinating Individually Measured Phenotypes to Advance Mental Health Research
NIH RePORTER · NIH RePORTER 11138581 (opens the source filing in a new tab)
Grant
R00 · $249k · non-dilutive
Jun 12, 2024
UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WANG, BINGKAI · NIAID · award ends May 31, 2027 · Improving the design and statistical analysis of cluster-randomized trials on tropical infectious diseases
NIH RePORTER · NIH RePORTER 11113968 (opens the source filing in a new tab)
Grant
R01 · $756k · non-dilutive
May 15, 2024
UNIVERSITY OF SOUTH FLORIDA · PI ZHAO, JINYING · NIA · award ends Apr 30, 2029 · Brain and blood N-glycome profiling in Alzheimer's disease
NIH RePORTER · NIH RePORTER 11321443 (opens the source filing in a new tab)
Trial
NA registered
Nov 11, 2023
Thymus Neoplasms · ACTIVE_NOT_RECRUITING · sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
ClinicalTrials.gov · NCT06189183 (opens the source filing in a new tab)
Trial
NA registered
Sep 12, 2023
Gestational Trophoblastic Neoplasia · RECRUITING · sponsor: Peking Union Medical College Hospital · Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6
ClinicalTrials.gov · NCT06028672 (opens the source filing in a new tab)
Trial
NA registered
Sep 11, 2023
Multiple Sclerosis, Demyelinating Disorder, Autoimmune Diseases · COMPLETED · sponsor: Kristin Zhao, PhD · Epidural Stimulation in Multiple Sclerosis
ClinicalTrials.gov · NCT06019611 (opens the source filing in a new tab)
Grant
R01 · $679k · non-dilutive
Sep 1, 2023
UNIVERSITY OF CALIFORNIA AT DAVIS · PI RIDGWAY, WILLIAM M · NIDDK · award ends Jun 30, 2027 · Mechanistic and Therapeutic Role of the TLR4 Signaling Pathway in Type 1 Diabetes
NIH RePORTER · NIH RePORTER 11123184 (opens the source filing in a new tab)
Trial
Study registered
Jul 15, 2023
Breast Cancer · COMPLETED · sponsor: Fudan University · 18F-fluoroestradiol (18F-FES) PET/CT Guided First-line Treatment for HR+/HER2- Metastatic Breast Cancer Patients
ClinicalTrials.gov · NCT06655545 (opens the source filing in a new tab)
Grant
U24 · $880k · non-dilutive
Apr 15, 2023
UNIVERSITY OF PENNSYLVANIA · PI DAVATZIKOS, CHRISTOS · NINDS · award ends Mar 31, 2028 · The Neuroimaging Brain Chart Software Suite
NIH RePORTER · NIH RePORTER 11087713 (opens the source filing in a new tab)
Grant
R00 · $249k · non-dilutive
Apr 1, 2023
RESEARCH INST OF FOX CHASE CAN CTR · PI FENG, WEIRAN · NCI · award ends Apr 30, 2028 · Mechanisms and vulnerabilities of ERG-driven luminal fate in prostate cancer
NIH RePORTER · NIH RePORTER 11231970 (opens the source filing in a new tab)
Grant
U24 · $876k · non-dilutive
Sep 1, 2022
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ZHANG, GUO-QIANG · NIMH · award ends Jun 30, 2027 · Engagement and outreach to achieve a FAIR data ecosystem for the BICAN
NIH RePORTER · NIH RePORTER 11121778 (opens the source filing in a new tab)
Grant
R35 · $426k · non-dilutive
Sep 1, 2022
OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI ZHAO, MENG · NIGMS · award ends Jun 30, 2027 · The role of mitochondrial regulation in cell lineage specification and function
NIH RePORTER · NIH RePORTER 11123093 (opens the source filing in a new tab)
Grant
R01 · $560k · non-dilutive
Aug 12, 2022
PURDUE UNIVERSITY · PI LIU, SA · NIEHS · award ends May 31, 2028 · Addressing Tetrachloroethylene Exposure in an Impacted Community: Residents' Concerns, Neurotoxic Effects, and Exposure Reduction
NIH RePORTER · NIH RePORTER 10833697 (opens the source filing in a new tab)
Trial
PHASE3 registered
Jun 20, 2022
Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: Guangdong Association of Clinical Trials · MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)
ClinicalTrials.gov · NCT04841811 (opens the source filing in a new tab)
Grant
R01 · $523k · non-dilutive
May 19, 2022
UNIVERSITY OF PENNSYLVANIA · PI MANKOFF, DAVID A. · NCI · award ends Apr 30, 2027 · PET Imaging of Glutamine Metabolism and Glutamate Transport to Guide Metabolically Targeted Therapy in Triple-Negative Breast Cancer
NIH RePORTER · NIH RePORTER 11082216 (opens the source filing in a new tab)
Grant
R16 · $150k · non-dilutive
May 10, 2022
NORTH CAROLINA CENTRAL UNIVERSITY · PI YANG, XIAOHE · NIGMS · award ends Apr 30, 2027 · In utero exposure to alcohol-induced mammary stem cell deregulation and tumor risk later in life.
NIH RePORTER · NIH RePORTER 11077802 (opens the source filing in a new tab)
Grant
R01 · $447k · non-dilutive
May 1, 2022
INDIANA UNIVERSITY INDIANAPOLIS · PI DONG, X. CHARLIE · NIAAA · award ends Mar 31, 2027 · The pathophysiological function of PNPLA3-148M variant in alcohol-induced liver injury
NIH RePORTER · NIH RePORTER 11055411 (opens the source filing in a new tab)
Grant
R01 · $447k · non-dilutive
May 1, 2022
INDIANA UNIVERSITY INDIANAPOLIS · PI DONG, X. CHARLIE · NIAAA · award ends Mar 31, 2027 · The pathophysiological function of PNPLA3-148M variant in alcohol-induced liver injury
NIH RePORTER · NIH RePORTER 11325419 (opens the source filing in a new tab)
Grant
R35 · $410k · non-dilutive
Sep 15, 2021
UNIVERSITY OF CHICAGO · PI ZHAO, MINGLEI · NIGMS · award ends Jun 30, 2026 · Structural and Functional Studies of Molecular Machines Involved in Chemical Modifications of Macromolecules
NIH RePORTER · NIH RePORTER 11124643 (opens the source filing in a new tab)
Grant
K25 · $130k · non-dilutive
Jul 1, 2021
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LIU, SHELLEY HAN · NICHD · award ends Jun 30, 2026 · Improving precision in modeling childhood executive function trajectories using psychometrics
NIH RePORTER · NIH RePORTER 11184454 (opens the source filing in a new tab)
Grant
R01 · $697k · non-dilutive
Jun 18, 2021
UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI YUSUF, NABIHA · NIAID · award ends May 31, 2027 · Role of Trem1 in ultraviolet radiation-induced immune suppression
NIH RePORTER · NIH RePORTER 11091999 (opens the source filing in a new tab)
Grant
R35 · $460k · non-dilutive
Jun 1, 2021
SCRIPPS RESEARCH INSTITUTE, THE · PI YANG, XIANG-LEI · NIGMS · award ends Aug 31, 2026 · Link extracellular function of tRNA synthetase with pathological mechanism of disease
NIH RePORTER · NIH RePORTER 11103367 (opens the source filing in a new tab)
Grant
R01 · $371k · non-dilutive
Apr 1, 2021
UNIVERSITY OF GEORGIA · PI ZELTNER, NADJA · NINDS · award ends Jun 30, 2030 · Genipin’s ECM Crosslinking Action as an Agent to Prevent Neurodegeneration in Familial Dysautonomia
NIH RePORTER · NIH RePORTER 11224362 (opens the source filing in a new tab)
Grant
R35 · $366k · non-dilutive
Jul 1, 2020
UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI DONG, XIAOWEI · NIGMS · award ends Jun 30, 2026 · Novel Formulation Technology to Enhance Oral Absorption of Water-insoluble Drugs
NIH RePORTER · NIH RePORTER 10889188 (opens the source filing in a new tab)
Trial
NA registered
Jan 1, 2020
Lumbar Degenerative Disease · ENROLLING_BY_INVITATION · sponsor: Qianfoshan Hospital · The Study of INTRA Spine Non Fusion Technique in the Treatment of Lumbar Degenerative Disease
ClinicalTrials.gov · NCT06075966 (opens the source filing in a new tab)
Grant
R01 · $3k · non-dilutive
Aug 1, 2016
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CHEN, YAN · NEI · award ends Dec 31, 2025 · Aberrant RPE mTORC1 signaling in dysregulation of choroid homeostasis
NIH RePORTER · NIH RePORTER 11092736 (opens the source filing in a new tab)
Grant
R01 · $637k · non-dilutive
Jul 21, 2016
MEDICAL COLLEGE OF WISCONSIN · PI CHEN, YI-GUANG · NIDDK · award ends Jun 30, 2027 · Mechanistic and therapeutic role of the CD137-CD137L axis in Type 1 Diabetes
NIH RePORTER · NIH RePORTER 11123344 (opens the source filing in a new tab)
Grant
R01 · $471k · non-dilutive
Jul 1, 2009
INDIANA UNIVERSITY INDIANAPOLIS · PI YANG, X. FRANK · NIAID · award ends May 31, 2028 · Regulatory Network of the Lyme Disease Pathogen
NIH RePORTER · NIH RePORTER 11088925 (opens the source filing in a new tab)
Grant
T32 · $351k · non-dilutive
May 1, 2005
UNIVERSITY OF PENNSYLVANIA · PI MANKOFF, DAVID A. · NIBIB · award ends Jun 30, 2030 · Research Track Radiology Residency
NIH RePORTER · NIH RePORTER 11095314 (opens the source filing in a new tab)
Grant
P30 · $111k · non-dilutive
Dec 1, 1996
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LAI, JENNIFER C. · NIDDK · award ends May 31, 2028 · Patient-Facing Research Core
NIH RePORTER · NIH RePORTER 11123389 (opens the source filing in a new tab)
Grant
P30 · $134k · non-dilutive
Dec 1, 1996
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WANG, BRUCE MAO ZHENG · NIDDK · award ends May 31, 2028 · Liver Gene Analysis Core
NIH RePORTER · NIH RePORTER 11123386 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75principal investigator ZHANG, HANRUI is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator LAI, JIANN-JYH is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator YANG, XINAN HOLLY is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator YANG, XUEXIAN is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator YANG, XIANGDONG WILLIAM is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator LIU, SIMIN is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator DONG, XIAOGUANG is named on this company's filings
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75principal investigator CHEN, YU-CHIH is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator CHEN, YAN-TING is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75principal investigator QI, XIN is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the trial record at 0.26same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Investigators

The principal investigators named on the grants below. Each links to their federal grant record and every other company traced to their work.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Study registered, no phase assigned: Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
4w agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)
8w agoTrial registeredSource (opens the source filing in a new tab)
NIH R01 · $0.4M · The pathophysiological function of PNPLA3-148M variant in alcohol-induced liver injury
3mo agoGrant renewalSource (opens the source filing in a new tab)
Phase II trial registered: CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
5mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
5mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase I trial registered: CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases
7mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases
7mo agoTrial recruitingSource (opens the source filing in a new tab)
NIH R21 · $0.2M · Elucidation of the alcohol effect on tumor suppressor genes
11mo agoNew grantSource (opens the source filing in a new tab)
Study registered, no phase assigned: Early Movers Pilot Intervention
11mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Early Movers Pilot Intervention
11mo agoTrial completedSource (opens the source filing in a new tab)
Study registered, no phase assigned: Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy
Jul 2025Trial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy
Jul 2025Trial recruitingSource (opens the source filing in a new tab)
NIH R35 · $0.4M · Novel Formulation Technology to Enhance Oral Absorption of Water-insoluble Drugs
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R03 · $0.1M · Novel TNF Secretion Assays
Jun 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Regulation of ATAD3A in TDP43-associated ALS/FTD
Jun 2025New grantSource (opens the source filing in a new tab)
NIH R35 · $0.4M · Structural and Functional Studies of Molecular Machines Involved in Chemical Modifications of Macromolecules
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.3M · Replication fork protection and innate immune response
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH T32 · $0.4M · Research Track Radiology Residency
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH U24 · $0.9M · Engagement and outreach to achieve a FAIR data ecosystem for the BICAN
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R35 · $0.4M · The role of mitochondrial regulation in cell lineage specification and function
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.8M · Elucidating the Link Between Oral Health and Dementia Subtypes: A Multifaceted Study on the Biological Pathways and Social Determinants
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Mechanistic and Therapeutic Role of the TLR4 Signaling Pathway in Type 1 Diabetes
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.4M · Genipin’s ECM Crosslinking Action as an Agent to Prevent Neurodegeneration in Familial Dysautonomia
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Extending neutrophil survival in neutropenia-related pneumonia
Jun 2025New grantSource (opens the source filing in a new tab)
NIH K25 · $0.1M · Improving precision in modeling childhood executive function trajectories using psychometrics
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R21 · $0.2M · Injectable 3D-Clustered Human Fibroblastic Reticular Cells for Expanding Regulatory T Cells
Jun 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Mechanistic and therapeutic role of the CD137-CD137L axis in Type 1 Diabetes
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.8M · Human antibodies as broad alphavirus immunotherapeutics
Jun 2025New grantSource (opens the source filing in a new tab)
NIH R35 · $0.5M · Link extracellular function of tRNA synthetase with pathological mechanism of disease
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.5M · Regulatory Network of the Lyme Disease Pathogen
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH P30 · $0.1M · Patient-Facing Research Core
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH P30 · $0.1M · Liver Gene Analysis Core
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.0M · Aberrant RPE mTORC1 signaling in dysregulation of choroid homeostasis
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R00 · $0.2M · Improving the design and statistical analysis of cluster-randomized trials on tropical infectious diseases
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.3M · Protein-Derived Cofactor in Bifunctional Enzyme KatG from Mycobacterium tuberculosis
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.5M · Intelligent and Personalized Online Adaptive Proton Therapy
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH U24 · $0.9M · The Neuroimaging Brain Chart Software Suite
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Role of Trem1 in ultraviolet radiation-induced immune suppression
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH U24 · $1.6M · Coordinating Individually Measured Phenotypes to Advance Mental Health Research
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.4M · CDK6-dependent metabolic reprogramming in KSHV pathogenesis
May 2025Grant renewalSource (opens the source filing in a new tab)
Study registered, no phase assigned: 18F-fluoroestradiol (18F-FES) PET/CT Guided First-line Treatment for HR+/HER2- Metastatic Breast Cancer Patients
May 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: 18F-fluoroestradiol (18F-FES) PET/CT Guided First-line Treatment for HR+/HER2- Metastatic Breast Cancer Patients
May 2025Trial completedSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Using 2D and 3D adrenal gland tissues to investigate developmental and disease paradigms
May 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.8M · Characterizing Family Structure, Care Utilization, and Well-Being among Persons with ADRD in the Asian Region
May 2025New grantSource (opens the source filing in a new tab)
NIH R16 · $0.1M · In utero exposure to alcohol-induced mammary stem cell deregulation and tumor risk later in life.
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.8M · Brain and blood N-glycome profiling in Alzheimer's disease
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R00 · $0.2M · Mechanisms and vulnerabilities of ERG-driven luminal fate in prostate cancer
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Addressing Tetrachloroethylene Exposure in an Impacted Community: Residents' Concerns, Neurotoxic Effects, and Exposure Reduction
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.4M · The pathophysiological function of PNPLA3-148M variant in alcohol-induced liver injury
Apr 2025Grant renewalSource (opens the source filing in a new tab)
Study registered, no phase assigned: Epidural Stimulation in Multiple Sclerosis
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: Epidural Stimulation in Multiple Sclerosis
Apr 2025Trial completedSource (opens the source filing in a new tab)
NIH R01 · $0.5M · PET Imaging of Glutamine Metabolism and Glutamate Transport to Guide Metabolically Targeted Therapy in Triple-Negative Breast Cancer
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R21 · $0.2M · Wirelessly Actuated Ciliary Stent for Minimally Invasive Treatment of Cilia Dysfunction
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Immunobiology of a novel human DAMP receptor, its murine homolog, & their ligand
Feb 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.3M · Asprosin, body weight, and risk of type 2 diabetes in U.S. men and women
Feb 2025Grant renewalSource (opens the source filing in a new tab)
Study registered, no phase assigned: Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6
Feb 2025Trial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: The Study of INTRA Spine Non Fusion Technique in the Treatment of Lumbar Degenerative Disease
Jan 2025Trial registeredSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

PHASE2 registered

PHASE1 registered

R21 · $228k · non-dilutive

R03 · $149k · non-dilutive

R01 · $738k · non-dilutive

R01 · $677k · non-dilutive

R21 · $231k · non-dilutive

R01 · $844k · non-dilutive

R01 · $841k · non-dilutive

R01 · $718k · non-dilutive

R35 · $687k · non-dilutive

R21 · $181k · non-dilutive

R01 · $578k · non-dilutive

R21 · $123k · non-dilutive

R21 · $222k · non-dilutive

R61 · $345k · non-dilutive

F99 · $3k · non-dilutive

R01 · $256k · non-dilutive

NA registered

NA registered

R01 · $404k · non-dilutive

R01 · $313k · non-dilutive

R01 · $340k · non-dilutive

R01 · $775k · non-dilutive

R21 · $198k · non-dilutive

R01 · $541k · non-dilutive

U24 · $1.6M · non-dilutive

R00 · $249k · non-dilutive

R01 · $756k · non-dilutive

NA registered

NA registered

NA registered

R01 · $679k · non-dilutive

Study registered

U24 · $880k · non-dilutive

R00 · $249k · non-dilutive

U24 · $876k · non-dilutive

R35 · $426k · non-dilutive

R01 · $560k · non-dilutive

PHASE3 registered

R01 · $523k · non-dilutive

R16 · $150k · non-dilutive

R01 · $447k · non-dilutive

R01 · $447k · non-dilutive

R35 · $410k · non-dilutive

K25 · $130k · non-dilutive

R01 · $697k · non-dilutive

R35 · $460k · non-dilutive

R01 · $371k · non-dilutive

R35 · $366k · non-dilutive

NA registered

R01 · $3k · non-dilutive

R01 · $637k · non-dilutive

R01 · $471k · non-dilutive

T32 · $351k · non-dilutive

P30 · $111k · non-dilutive

P30 · $134k · non-dilutive